World's Best Scientists 2026 revealed!
Joseph O. Moore

Joseph O. Moore

D-Index & Metrics

Medicine

D-Index
82
Citations
28210
World Ranking
15984
National Ranking
8044

Joseph O. Moore publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joseph O. Moore sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 313 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joseph O. Moore D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph O. Moore sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joseph O. Moore is affiliated with Duke University in the United States. Their research spans two main fields: Medicine and Engineering. Within these fields, they have contributed to subfields such as Hematology, Molecular Biology, Control and Systems Engineering, Ocean Engineering, and Mechanical Engineering.

The scientist's work addresses a range of topics including:

  • Hydraulic Fracturing and Reservoir Analysis
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Drilling and Well Engineering
  • Histone Deacetylase Inhibitors Research
  • Robotic Path Planning Algorithms
  • Advanced Control Systems Optimization

Joseph O. Moore has published extensively, with notable recurring venues for publication including:

  • arXiv (Cornell University)
  • Blood
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
  • Journal of the National Comprehensive Cancer Network
  • Applied Thermal Engineering

The following recent papers highlight the scope and diversity of their research output:

  • "Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology" (2020), Journal of the National Comprehensive Cancer Network
  • "Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology" (2024), Journal of the National Comprehensive Cancer Network
  • "Utah FORGE: Well 16A(78)-32 Drilling Data" (2021), OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
  • "Overview and outlook of thermal processes in geothermal energy extraction" (2025), Applied Thermal Engineering
  • "Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (2021), Cancer Investigation

Collaboration plays an important part in Joseph O. Moore's research activities. Frequent co-authors include:

  • Marin Kobilarov
  • Deedra Nicolet
  • Krzysztof Mrózek
  • William Blum
  • Jonathan E. Kolitz

Best Publications

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Intensity of renal support in critically ill patients with acute kidney injury

    Paul M. Palevsky;Jane Hongyuan Zhang;Theresa Z. O'Connor;Glenn M. Chertow

  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

    Mayer Rj;Davis Rb;Schiffer Ca;Berg Dt

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

    Richard M. Stone;Deborah T. Berg;Stephen L. George;Richard K. Dodge

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

    W. P. Peters;Elizabeth Shpall;Roy Jones;G. A. Olsen

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

    Guido Marcucci;Krzysztof Mrózek;Amy S. Ruppert;Kati Maharry

  • NCCN Clinical Practice Guidelines Acute myeloid leukemia.

    O'Donnell Mr;Abboud Cn;Altman J;Appelbaum Fr

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered

    John C. Byrd;Richard K. Dodge;Andrew Carroll;Maria R. Baer

  • Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Susan O'Brien;Joseph O. Moore;Thomas E. Boyd;Loree M. Larratt

  • A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy

    Isidore Tepler;Laurence Elias;John W. Smith;Mohamad Hussein

  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

    Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

  • Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

    Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

  • Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

    Eric J Feldman;Joseph Brandwein;Richard Stone;Matt Kalaycio

  • RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

    Jason H. Mendler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

    Claudia D. Baldus;Stephan M. Tanner;Amy S. Ruppert;Susan P. Whitman

  • NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines

    Richard T. Hoppe;Ranjana H. Advani;Weiyun Z. Ai;Richard F. Ambinder

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Richard A. Larson
Richard A. Larson University of Chicago
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Bayard L. Powell
Bayard L. Powell Wake Forest University
J. Brice Weinberg
J. Brice Weinberg Duke University
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Richard Stone
Richard Stone Harvard University
Susan P. Whitman
Susan P. Whitman The Ohio State University
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering a career in Medicine or healthcare, several online degrees and certifications provide flexible and affordable ways to advance your education. Key pathways include nursing, pharmacy, health information management, and medical billing and coding.

Many current registered nurses look to msn to dnp programs online to achieve the Doctor of Nursing Practice degree, which opens doors to advanced leadership and clinical roles. Aspiring pharmacists are increasingly exploring online pharmacy school cost to find affordable and flexible PharmD programs.

For those interested in the data and administrative side of healthcare, completing rhia certification programs online can lead to specialized roles in health information management. Medical billing and coding is another in-demand field, and earning a medical coding certification online offers a quick entry into the healthcare workforce.

Each of these online pathways provides unique opportunities for professional growth in the healthcare sector, often with lower tuition and greater flexibility than traditional on-campus programs.

Best Scientists Citing Joseph O. Moore

Trending Scientists

Recently Published Articles